Summary
Purpose To investigate the toxicity profile, activity, pharmacokinetics, and pharmacodynamics of pemetrexed in leukemia. Patients and Methods Patients with refractory or relapsed acute leukemia were eligible. A phase I 3+3 design was implemented. Pemetrexed was infused intravenously (IV) over 25 min with vitamin supplementation. Courses were repeated every 3 to 4 weeks according to toxicity and efficacy. The starting dose of 900 mg/m2 was escalated by approximately 33% until the dose-limiting toxicity (DLT) was determined. Results Twenty patients with acute myeloid (AML) or lymphocytic (ALL) leukemia received therapy. The main non-hematologic adverse event was liver dysfunction at several dose levels, including 2 DLTs at 3,600 mg/m2. One patient with ALL (3,600 mg/m2 dose level) achieved a partial response. Pemetrexed pharmacokinetics were linear with escalated dosing. Elevated plasma deoxyuridine was observed in a subset of patients following pemetrexed infusion, but was not correlated with dose levels. Changes in the nucleotide pools of circulating mononuclear cells were observed, but were variable. Conclusions The recommended phase II dose of pemetrexed for future leukemia studies is 2,700 mg/m2 IV over 25 min every 3 to 4 weeks with vitamin supplementation. Deoxyuridine levels did not increase with increasing pemetrexed dose, suggesting pemetrexed inhibition of thymidylate synthase (TS) may be saturated by the 900 mg/m2 dose level. However, no firm conclusion can be made regarding TS saturation in tumor cells. While tolerable, pemetrexed monotherapy had limited activity in this highly refractory population. Exploration of pemetrexed in combination with other active agents in leukemia is a reasonable future endeavor.
Similar content being viewed by others
References
American Cancer Society (2008) Cancer Facts and Figures 2008. American Cancer Society. Available at: http://www.cancer.org. Accessed 1 Sep 2009
Kantarjian HM (2007) Therapy for elderly patients with acute myeloid leukemia: a problem in search of solutions. Cancer 109:1007–1010
Adjei AA (2000) Pemetrexed: a multitargeted antifolate agent with promising activity in solid tumors. Ann Oncol 11:1335–1341
Grem J (1990) Fluorinated pyrimidines. In: Chabner BA, Collins JM (eds) Cancer chemotherapy: principles and practice. Lippincott, Philadelphia, pp 180–224
Schilsky RL (1992) Antimetobolites. In: Perry MC (ed) The chemotherapy source book. Williams and Wilkins, Baltimore, pp 301–315
Alimta Prescribing Information (2009) Eli Lilly and Company, Indianapolis, IN. Available at: http://pi.lilly.com/us/alimta-pi.pdf. Accessed 1 Sep 2009
Takimoto CH, Hammond-Thelin LA, Latz JE, Forero L et al (2007) Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer. Clin Cancer Res 13:2675–2683
Niyikiza C, Baker SD, Seitz DE, Walling JM et al (2002) Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 1:545–552
Hanauske AR, Chen V, Paoletti P, Niyikiza C (2001) Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 6:363–373
Miller DS, Blessing JA, Krasner CN, Mannel RJ et al (2009) A phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol 27:2686–2691
Cullen MH, Zatloukal P, Sorenson S, Novello S et al (2008) A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 19:939–945
Latz JE, Chaudhary A, Ghosh A, Johnson RD (2006) Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. Cancer Chemother Pharmacol 57:401–411
Beal SL, Sheiner LB (1992) NONMEM User's Guide. NONMEM Project Group, University of California at San Francisco. San Francisco, CA
Plunkett W, Hug V, Keating MJ, Chubb S (1980) Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res 40:588–591
Gandhi V, Plunkett W, Du M, Ayres M, Estey EH (2002) Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia. J Clin Oncol 20:665–673
Rodriguez CO Jr, Plunkett W, Paff MT, Du M et al (2000) High-performance liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells. J Chromatogr B Biomed Sci Appl 745:421–430
Sherman PA, Fyfe JA (1989) Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers. Anal Biochem 180:222–226
Li KM, Rivory LP, Clarke SJ (2007) Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules. Br J Cancer 97:1071–1076
Malempati S, Nicholson HS, Reid JM, Blaney SM et al (2007) Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group. J Clin Oncol 25:1505–1511
Chen VJ, Bewley JR, Andis SL et al (1998) Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. Br J Cancer 78(Suppl 3):27–34
Ohe Y, Ichinose Y, Nakagawa K, Tamura T et al (2008) Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res 14:4206–4212
Acknowledgments
This study was funded by a grant from Lilly USA, LLC, Indianapolis, IN, USA. The authors wish to acknowledge the patients and study personnel who participated in this clinical trial. The authors would like to acknowledge the expert assistance of Guochang George Zhu, MD (Eli Lilly and Company), who facilitated many aspects of protocol implementation and support. The authors wish to thank Lori Kornberg, PhD (i3 Statprobe, funded by Lilly USA, LLC) for assistance in the technical writing of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Abdel-Karim, I., Plunkett, W.K., O’Brien, S. et al. A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia. Invest New Drugs 29, 323–331 (2011). https://doi.org/10.1007/s10637-009-9369-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-009-9369-7